2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transformed indolent lymphoma outcomes similar to de novo diffuse large B-cell lymphoma after autologous hematopoietic stem cell transplantation (AHCT), but not allogeneic HCT (allo-HCT)
    Meeting Abstract

    Pathak, P.; Shah, G. L.; Tsyvkin, E.; Maloy, M.; Knezevic, A.; Devlin, S. M.; Giralt, S. A.; Matasar, M. J.; Moskowitz, C. H.; Sauter, C. S.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Toxicities associated with high dose chemotherapy and autologous stem cell transplantation in older patients with non-Hodgkin lymphoma
    Meeting Abstract

    Dahi, P. B.; Rondon Clavo, C.; Maloy, M.; Seier, K.; Devlin, S. M.; Robinson, K.; Scordo, M.; Shah, G. L.; Tamari, R.; Matasar, M. J.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Pharmacokinetics and toxicities after Evomela® (propylene glycol free melphalan) with hematopoietic stem cell transplant (HCT) for multiple myeloma (MM), AL amyloidosis (AL), lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS)
    Meeting Abstract

    Shah, G. L.; Landau, H.; Sarubbi, C.; Schofield, R.; Lin, A.; Bhatt, V.; Harnicar, S.; Devlin, S. M.; Castro-Malaspina, H.; Chung, D. J.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
    Meeting Abstract

    Blum, K. A.; Abramson, J.; Maris, M.; Flinn, I.; Goy, A.; Mertz, J.; Sims, R.; Garner, F.; Senderowicz, A.; Younes, A.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study): A defined composition CD19-directed CAR T cell product with potential for outpatient administration
    Meeting Abstract

    Abramson, J. S.; Siddiqi, T.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Wang, M.; Forero-Torres, A.; Albertson, T.; Dehner, C.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin's lymphoma (AMC-075)
    Journal Article

    Ramos, J. C.; Sparano, J. A.; Rudek, M. A.; Moore, P. C.; Cesarman, E.; Reid, E. G.; Henry, D.; Ratner, L.; Aboulafia, D.; Lee, J. Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
    Journal Article

    Horwitz, S. M.; Koch, R.; Porcu, P.; Oki, Y.; Moskowitz, A.; Perez, M.; Myskowski, P.; Officer, A.; Jaffe, J. D.; Morrow, S. N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
    Journal Article

    Flinn, I. W.; O’Brien, S.; Kahl, B.; Patel, M.; Oki, Y.; Foss, F. F.; Porcu, P.; Jones, J.; Burger, J. A.; Jain, N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The optimal regimen of brentuximab vedotin for CD30(+) cutaneous lymphoma: Are we there yet?
    Journal Article

    Geller, S.; Myskowski, P. L.; Kim, Y. H.; Moskowitz, A.; Horwitz, S.
    British Journal of Dermatology (2018)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
    Journal Article

    Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save